NCT00005633View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1999

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

OVA BiP peptide

BIOLOGICAL

gp209-2M antigen

BIOLOGICAL

recombinant 70-kD heat-shock protein

BIOLOGICAL

tyrosinase peptide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00005633 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter